Study S001826

Dose-response Relationship of Five Dose Levels of NNC90-1170 and Placebo on Glycaemic Control in Type 2 Diabetic Patients Compared to OHA Treatment. A 12-week Multi-centre, Double-blind, Randomised, Parallel Group Trial With an Open Labelled OHA Arm

ClinicalTrials.gov record

Registration

Registration: NCT01509755
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED
Enrollment: 196
Start: 2000-10
Primary completion: 2001-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:placebo; DRUG:liraglutide; DRUG:glimepiride
Results posted: FALSE

Registered primary outcomes

HbA1c (glycosylated haemoglobin) []

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023483	Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care	2015	Systematic review	PMID 25504028 DOI	registry reference RESULT:25504028
R0023713	Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Madsbad S, Diabetes care	2004	Randomized trial	PMID 15161785 DOI	registry reference RESULT:15161785